DUBLIN--(BUSINESS WIRE)--The "Drug Overview: Saphris" report has been added to ResearchAndMarkets.com's offering.
Saphris (Allergan/Lundbeck/Meiji Seika) contains the atypical antipsychotic asenapine, which acts as a dopamine D2 and serotonin 5-HT2A antagonist. The drug was originally developed by Organon and Schering-Plough, and became part of Merck & Co's portfolio after the company's $41bn acquisition of Schering-Plough in 2009.
Saphris received US approval for its first bipolar disorder indication in August 2009 and was launched in the US in October 2009. In September 2010, asenapine received its first EU approval, where Lundbeck retains all commercial rights to the brand. Lundbeck launched asenapine (under the brand name Sycrest) in the EU in April 2011. In December 2013, Allergan (formerly Forest Laboratories) announced that it would acquire exclusive rights from Merck & Co for Saphris in the US. The deal closed in January 2014.
Allergan indicated additional approvals for bipolar depression and maintenance, as well as the launch of a new lower dose for Saphris, in the first quarter of 2017. However, Saphris's US label does not reflect the drug's approval in bipolar depression.
For more information about this report visit https://www.researchandmarkets.com/research/g9nrx6/saphris?w=4
